Alembic's Bosutinib Approval & Market Opportunity

  Published 1 year ago

Alembic Pharmaceuticals received USFDA approval for Bosutinib tablets, a generic equivalent to Bosulif, targeting a $291 million market. Alembic boasts 223 total ANDA approvals and strong R&D/manufacturing capabilities.

  • ANDA approved for Bosutinib, treating CML.
  • $291M US market size (ending March 2025).
  • Alembic: 223 USFDA approvals to date.

You might like these

Airtel Delhi Outage Impacts Calls

Denosumab Biosimilars Approved in Europe for Bone Conditions

Vikram Solar Powers Khavda

Adani Energy Wins ₹1,660 Crore Transmission Project

Apple Unveils AI Open-Source Plan, OS Redesign

Honasa Consumer: Profit Declines, Sales Rise

Bajaj Auto: Strong Profit & KTM Focus

News that matters the most ⚡